India Considers Moratorium On Public Pharma Price Caps
This article was originally published in PharmAsia News
Executive Summary
Indian authorities are considering a two- or three-year reprieve from drug price controls for public-sector pharmaceutical companies. That would mean firms such as Bengal Chemicals, Hindustan Antibiotics and Indian Drug and Pharmaceuticals would not have to comply with the government-ordered caps on the price of their products. The effort to help the PSUs, which make only drugs that fall under price controls, comes in response to increases in the prices of raw materials used for drugs. Such firms also supply drugs to institutions at prices already fixed. The private pharma industry has yet to react to the proposal. (Click here for more